Serpins for diagnosis and therapy in cancer

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 13, Issue 2, 2013, Pages 123-132

  Zheng, Donghang ^a   Chen, Hao ^a   Davids, Jennifer ^a   Bryant, Marsha ^b   Lucas, Alexandra ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cancer; Maspin; Neuroserpin; PAI 1; PEDF; Serp 1; Serpin

Indexed keywords

ALPHA 1 ANTITRYPSIN; FAS LIGAND; GELATINASE A; KALLISTATIN; MASPIN; MYXOMA VIRUS DERIVED SERPIN; NEUROSERPIN; PIGMENT EPITHELIUM DERIVED FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEASE INHIBITOR 9; PROTEASE NEXIN I; PROTEIN BAX; PROTEIN BCL 2; PROTEIN CDC42; RAC1 PROTEIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SERPINB13; SERPINB3; SERPINB4; STROMELYSIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CHONDROSARCOMA; COLON CANCER; ENDOMETRIUM CANCER; GENE EXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LIVER CANCER; LUNG CANCER; MELANOMA; METASTASIS; NEOPLASM; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN STRUCTURE; RETINOBLASTOMA; STOMACH CANCER; UTERINE CERVIX CANCER;

ANIMALS; HUMANS; MODELS, MOLECULAR; NEOPLASMS; SERINE PROTEINASE INHIBITORS; SERPINS;

EID: 84888088851     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529X11313020005     Document Type: Article

References (105)

1. Lucas A., Liu L., Dai E., Bot I., Viswanathan K., Munuswamy-Ramunujam G., Davids J.A., Bartee M.Y., Richardson J., Christov A., Wang H., Macaulay C., Poznansky M., Zhong R., Miller L., Biessen E., Richardson M., Sullivan C., Moyer R., Hatton M., Lomas D.A., McFadden G. The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics. Adv. Exp. Med. Biol., 2009, 666, 132-156.
2. Ulisse S., Baldini E., Sorrenti S., D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets, 2009, 9, 32-71.
3. Dass K; Ahmad A; Azmi AS; Sarkar SH; Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev., 2008, 34, 122-136.
4. Bergheim I., Guo L., Davis M.A., Duveau I., Arteel G.E. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J. Pharmacol. Exp. Ther., 2006, 316, 592-600.
5. Gharaee-Kermani M., Hu B., Phan S.H., Gyetko M.R. The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy. Expert Opin. Investig. Drugs, 2008, 17, 905-916.
6. Fogo A.B. The role of angiotensin ii and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am. J. Kidney Dis., 2000, 35, 179-188.
7. Samarakoon R., Higgins S. P., Higgins C. E., Higgins P. J."TGF-_1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60csrc/ EGFRY845 and Rho/ROCK signaling," J. Mol. Cell Cardiol., 2008, 3, 527-538.
8. Gillespie E., Leeman S.E., Watts L.A., Coukos J.A., O'Brien M.J., Cerda S.R., Farraye F.A., Stucchi A.F. Plasminogen activator inhibitor-1 is increased in colonic epithelial cells from patients with colitis-associated cancer. J. Crohns. Colitis., 2012, Aug 22.
9. Baldini E., Sorrenti S., D'Armiento E., Di Matteo F.M., Catania A., Ulisse S. The urokinase plasminogen activating system in thyroid cancer: clinical implications. G. Chir., 2012, 33, 305-310.
10. Andres S.A., Edwards A.B., Wittliff J.L. Expression of urokinasetype plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance. J. Clin. Lab. Anal., 2012, 26, 93-103.
11. Czekay R.P., Wilkins-Port C.E., Higgins S.P., Freytag J., Overstreet J.M., Klein R.M., Higgins C.E., Samarakoon R., Higgins P.J. PAI-1: An Integrator of Cell Signaling and Migration. Int. J. Cell Biol., 2011, 2011, 562481.
12. Kamikubo Y., Neels J. G., and Degryse B. "Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein," Int. J. Biochem. Cell Biol., 2009, 41, 578-585.
13. Degryse B., Neels J. G., Czekay R. P., Aertgeerts K., Kamikubo Y. I., and Loskutoff D. J. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J. Biol. Chem., 2004, 279, 22595-22604.
14. Cartier-Michaud A., Malo M., Charrière-Bertrand C., Gadea G., Anguille C., Supiramaniam A., Lesne A., Delaplace F., Hutzler G., Roux P., Lawrence D.A., Barlovatz-Meimon G. Matrixbound PAI-1 supports cell blebbing via RhoA/ROCK1 signaling. PLoS One., 2012, 7, e32204
15. Webb D.J., Thomas K.S., Gonias S.L. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes mcf-7 cell growth. J. Cell Biol., 2001, 152, 741-752.
16. Fang H., Placencio V.R., Declerck Y.A. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J. Natl. Cancer Inst., 2012, 104, 1470-84.
17. Kwaan H.C., Wang J., Svoboda K., Declerck P.J. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br. J. Cancer, 2000, 82, 1702-1708.
18. Lademann U., Romer M.U., Jensen P.B., Hofland K.F., Larsen L., Christensen I.J., Brünner N. Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis. Eur. J. Cancer, 2005, 417, 1095-1100.
19. Romer M.U., Kirkebjerg D.A., Knud L.J., Hofland KF., Christensen I.J., Buhl-Jensen P., Almholt K., Lerberg Nielsen O., Brünner N., Lademann U. Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis. Thromb. Haemost., 2005, 94, 859-866.
20. Romer M.U., Larsen L., Offenberg H., Brünner N., Lademann U.A. Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway. Neoplasia, 2008, 10, 1083-1091.
21. Bajou K., Noel A., Gerard R.D., Masson V., Brunner N., Holst-Hansen C., Skobe M., Fusenig N.E., Carmeliet P., Collen D., Foidart J.M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med., 1998, 4, 923-928.
22. Bajou K., Maillard C., Jost M., Lijnen R.H., Gils A., Declerck P., Carmeliet P., Foidart J.M., Noel A. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene, 2004, 23, 6986-6990.
23. Bajou K., Peng H., Laug W.E., Maillard C., Noel A., Foidart J.M., Martial J.A., DeClerck Y.A. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell, 2008, 14, 324-334.
24. Nishioka N., Matsuoka T., Yashiro M., Hirakawa K., Olden K., Roberts J.D. Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo. Cancer Sci., 2012, 103, 228-232.
25. Gao F., Shi H. Y., Daughty C., Cella N., Zhang M. Maspin plays an essential role in early embryonic development. Development, 2004, 131, 1479-1489.
26. Dokras A., Gardner L. M., Kirschmann D. A., Seftor E.A., Hendrix M.J. The tumour suppressor gene maspin is differentially regulated in cytotrophoblasts during human placental development. Placenta, 2002, 23, 274-280.
27. Sheng S., Pemberton P. A., Sager R. Production, purification, and characterization of recombinant maspin proteins. J. Biol. Chem., 1994, 269, 30988-30993.
28. Zhang M., Magit D., Botteri F., Shi H.Y., He K., Li M., Furth P., Sager R. Maspin plays an important role in mammary gland development. Dev. Biol., 1999, 215, 278-287.
29. Ngamkitidechakul C., Burke J. M., O'Brien W. J., Twining S.S. Maspin: synthesis by human cornea and regulation of in vitro stromal cell adhesion to extracellular matrix. Invest. Ophthalmol. Vis. Sci., 2001, 42, 3135-3141.
30. Acikalin D., Oner U., Can C., Acikalin M.F., Colak E., Tumori. Predictive value of maspin and Ki-67 expression in transurethral resection specimens in patients with T1 bladder cancer. Tumori, 2012, 98, 344-50.
31. Berardi R., Santinelli A., Onofri A., Brunelli A., Pierantoni C., Pisa E., Pagliacci A., Stramazzotti D., Zuccatosta L., Mazzanti P., Sabbatini A., Gasparini S., Bearzi I., Cascinu S. Maspin expression is a favorable prognostic factor in non-small cell lung cancer. Anal. Quant. Cytol. Histol., 2012, 34, 72-78.
32. Yoshizawa K., Nozaki S., Kitahara H., Kato K., Noguchi N., Kawashiri S., Yamamoto E. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors. Oncol. Rep., 2011, 26, 1555-1560.
33. Lonardo F., Li X., Kaplun A., Soubani A., Sethi S., Gadgeel S., Sheng S. The natural tumor suppressor protein maspin and potential application in non small cell lung cancer. Curr. Pharm. Des., 2010, 16, 1877-1881.
34. Lei K.F., Liu B.Y., Jin X.L., Guo Y., Ye M., Zhu Z.G. Prognostic value of nuclear maspin expression for adjuvant 5-fluorouracilbased chemotherapy in advanced gastric cancer. Exp. Ther. Med., 2012, 3,993-998.
35. Gurzu S., Szentirmay Z., Toth E., Jung I. Possible Predictive Value of Maspin Expression in Colorectal Cancer. Recent Pat. Anticancer. Drug Discov., 2012, Sep 5.
36. Goulet B., Chan G., Chambers A.F., Lewis J.D. An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis. Biochem. Cell Biol., 2012, 90, 22-38.
37. Märkl B., Arnholdt H.M., Jähnig H., Schenkirsch G., Herrmann R.A., Haude K., Spatz H., Anthuber M., Schlimok G., Oruzio D. Shift from cytoplasmic to nuclear maspin expression correlates with shorter overall survival in node-negative colorectal cancer. Hum. Pathol., 2010, 41, 1024-1033.
38. Saito H., Masuda S., Wang Z.G., Takano Y. Cytoplasmic and nuclear maspin expression in lung carcinomas: an immunohistochemical study using tissue microarrays. Appl. Immunohistochem. Mol. Morphol., 2008, 16, 459-465.
39. Bettstetter M., Woenckhaus M., Wild P. J., Rümmele P., Blaszyk H., Hartmann A., Hofstädter F., Dietmaier W. Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J. Pathol., 2005, 205, 606-614.
40. Shi H. Y., Stafford L. J., Liu Z., Liu M., Zhang M. Maspin controls mammary tumor cell migration through inhibiting Rac1 and Cdc42, but not the RhoA GTPase. Cell Motil. Cytoskeleton, 2007, 64, 338-346.
41. Seftor R. E. B., Odero V. A., Seftor E. A. Maspin suppresses breast cancer invasiveness by modulating integrin expression and function. in Maspin, Georgetown: Landes Bioscience, 2002, pp. 84-95
42. Jiang N., Meng Y., Zhang S., Mensah-Osman E., Sheng S. Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene, 2002, 21, 4089-4098.
43. Tahmatzopoulos A., Sheng S., & Kyprianou N. Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene, 2005, 24, 5375-5383.
44. Nam E., Park C. Maspin suppresses survival of lung cancer cells through modulation of Akt pathway. Cancer Res. Treat., 2010, 42, 42-47.
45. Ben Shachar B., Feldstein O., Hacohen, D., Ginsberg D. The tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy. Mol. Cancer Res., 2010, 8, 363-372.
46. Liu J., Yin S., Reddy N., Spencer C., Sheng S. Bax mediates the apoptosis-sensitizing effect of maspin. Cancer Res., 2004, 64, 1703-1711.
47. Zhang W., Shi H. Y., Zhang M. Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer, 2005, 5, 50.
48. Lee S. J., Jang H., Park C. Maspin increases Ku70 acetylation and Bax-mediated cell death in cancer. Int. J. Mol. Med., 2012, 29, 225-230.
49. Cher M. L., Biliran H. R. Jr., Bhagat S., Meng Y., Che M., Lockett J., Abrams J., Fridman R., Zachareas M., Sheng S. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 7847-7852.
50. Sopel M., Kasprzyk I., & Berdowska I. Maspin and cerbB-2 expression in correlation with microvessel density in invasive ductal breast cancer. Folia Histochem. Cytobiol., 2005, 43, 109-116.
51. Song S.Y., Lee S.K., Kim D.H., Son H.J., Kim H.J., Lim Y.J., Lee W.Y., Chun H.K., Rhee J.C. Expression of maspin in colon cancers: its relationship with p53 expression and microvessel density. Dig. Dis. Sci., 2002, 47, 1831-1835.
52. Friedrich M. G., Toma M. I., Petri S., Cheng J.C., Hammerer P., Erbersdobler A., Huland H. Expression of Maspin in nonmuscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis. Eur. Urol., 2004, 45, 737-743.
53. Marioni G., D'Alessandro E., Giacomelli L., De Filippis C., Calgaro N., Sari M., Staffieri A., Blandamura S. Maspin nuclear localization is related to reduced density of tumour-associated micro-vessels in laryngeal carcinoma. Anticancer Res., 2006, 26, 4927-4932.
54. Marioni G., Staffieri C., Staffieri A., De Filippis C., Blandamura S. MASPIN tumour-suppressing activity in head and neck squamous cell carcinoma: emerging evidence and therapeutic perspectives. Acta Otolaryngol., 2009, 129, 476-480.
55. Chua R., Setzer S., Govindarajan B., Sexton D., Cohen C., Arbiser J.L. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. J. Am. Acad. Dermatol., 2009, 60, 758-766.
56. Li Z., Shi H. Y., Zhang M. Targeted expression of maspin in tumor vasculatures induces endothelial cell apoptosis. Oncogene, 2005, 24, 2008-2019.
57. Qin L., Zhang M. Maspin regulates endothelial cell adhesion and migration through an integrin signaling pathway. J. Biol. Chem., 2010, 285, 32360-32369.
58. Zhang S.X. Wang J.J., Gao G., Shao C., Mott R., Ma J.X. () Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J., 2006, 20, 323-325.
59. Takanohashi A., Yabe T., Schwartz J.P. Pigment epitheliumderived factor induces the production of chemokines by rat microglia. Glia, 2005, 51, 266-278.
60. Tsao Y.P., Ho T.C., Chen S.L., Cheng H.C. Pigment epitheliumderived factor inhibits oxidative stress-induced cell death by activation of extracellular signal-regulated kinases in cultured retinal pigment epithelial cells. Life Sci., 2006, 79, 545-550.
61. Bilak M.M. Corse AM, Bilak SR, Lehar M, Tombran-Tink J, Kuncl RW. Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. J. Neuropathol. Exp. Neurol., 1999, 58, 719-728
62. Tombran-Tink J., Chader G.G., Johnson L.V. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp. Eye Res., 1991, 53, 411-414
63. Steele F.R., Chader G.J., Johnson L.V., Tombran-Tink J. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc. Natl. Acad. Sci. U. S. A., 1993, 90, 1526-1530.
64. Doll J.A., Stellmach V.M., Bouck N.P., Bergh A.R., Lee C., Abramson L.P., Cornwell M.L., Pins M.R., Borensztajn J., Crawford S.E. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat. Med., 2003, 9, 774-780.
65. Hase R., Miyamoto M., Uehara H., Kadoya M., Ebihara Y., Murakami Y., Takahashi R., Mega S., Li L., Shichinohe T., Kawarada Y., Kondo S. Pigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in mice. Clin. Cancer Res., 2005, 11, 8737-8744.
66. Takenaka K. Yamagishi S., Jinnouchi Y., Nakamura K., Matsui T., Imaizumi T. Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci., 2005, 77, 3231-3241.
67. Uehara H., Miyamoto M., Kato K. Ebihara Y., Kaneko H., Hashimoto H., Murakami Y., Hase R., Takahashi R., Mega S., Shichinohe T., Kawarada Y., Itoh T., Okushiba S., Kondo S., Katoh H. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res., 2004, 64, 3533-3537.
68. Cheung L.W., Au S.C., Cheung A.N., Ngan H.Y., Tombran-Tink J., Auersperg N., Wong A.S. Pigment epithelium-derived factor is oestrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells. Endocrinology, 2006, 147, 4179-4191.
69. Ek E.T., Dass C.R., Contreras K.G., Choong P.F. PEDF-derived synthetic peptides exhibit antitumour activity in an orthotopic model of human osteosarcoma. J. Orthop. Res., 2007, 25, 1671-1680.
70. Matsumoto K., Ishikawa H., Nishimura D., Hamasaki K; Nakao K., Eguchi K., Antiangiogenic property of pigment epitheliumderived factor in hepatocellular carcinoma. Hepatology, 2004, 40, 252-259.
71. Abramson L.P., Stellmach V., Doll J.A., Cornwell M; Arensman R.M; Crawford S.E. Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model. J. Pediatr. Surg., 2003, 38, 336-342.
72. Abe R., Shimizu T., Yamagishi S., Shibaki A., Amano S., Inagaki Y., Watanabe H., Sugawara H., Nakamura H., Takeuchi M., Imaizumi T., Shimizu H. Overexpression of pigment epitheliumderived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am. J. Pathol., 2004, 164, 1225-1232.
73. Zhang L., Chen J., Ke Y., Mansel R.E., Jiang W.G. Downregulation of PEDF expression by r.ibozyme transgene in endothelial and lung cancer cells and its impact on angiogenesis in vitro. Oncol. Rep., 2005, 14, 1615-1619.
74. Crawford S.E., Stellmach V., Ranalli M., Huang X., Huang L., Volpert O., De Vries G.H., Abramson L.P., Bouck N. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J. Cell Sci., 2001, 114, 4421-4428.
75. Volpert O.V., Zaichuk T., Zhou W., Reiher F., Ferguson T.A., Stuart P.M., Amin M., Bouck N.P. Inducer-stimulated Fas targets activated endothelium for destruction by antiangiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat. Med., 2002, 8, 349-357.
76. Zhang T., Guan M., Xu C., Chen Y., Lu Y. Pigment epitheliumderived factor inhibits glioma cell growth in vitro and in vivo. Life Sci., 2007, 81, 1256-1263.
77. Lai L.J., Ho T.C. Pigment epithelial-derived factor inhibits c-FLIP expression and assists ciglitazone-induced apoptosis in hepatocellular carcinoma. Anticancer Res., 2011, 31, 1173-1180.
78. Halin S., Wikström P., Rudolfsson S.H., Stattin P., Doll J.A., Crawford S.E., Bergh A. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res., 2004, 64, 5664-5671.
79. Uehara H., Miyamoto M., Kato K., Ebihara Y., Kaneko H., Hashimoto H., Murakami Y., Hase R., Takahashi R., Mega S., Shichinohe T., Kawarada Y., Itoh T., Okushiba S., Kondo S., Katoh H. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res., 2004, 64, 3533-3537.
80. Guan, M., Yam, H.F., Su, B., Chan, K.P., Pang, C.P., Liu, W.W., Zhang, W.Z., Lu, Y. Loss of pigment epithelium derived factor expression in glioma progression. J. Clin. Pathol., 2003, 56, 277-282.
81. Sidle D.M., Maddalozzo J., Meier J.D., Cornwell M., Stellmach V., Crawford S.E. Altered pigment epithelium-derived factor and vascular endothelial growth factor levels in lymphangioma pathogenesis and clinical recurrence. Arch. Otolaryngol. Head Neck Surg., 2005, 131, 990-995.
82. Zhang L., Chen J., Ke Y., Mansel R.E., Jiang W.G. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome. Int. J. Mol. Med., 2006, 17, 937-944.
83. Zaichuk T.A., Shroff E.H., Emmanuel R., Filleur S., Nelius T., Volpert O.V. Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J. Exp. Med., 2004, 199, 1513-1522.
84. Garcia M., Fernandez-Garcia N.I., Rivas V., Carretero M., Escamez M.J., Gonzalez-Martin A., Medrano E.E., Volpert O., Jorcano J.L., Jimenez B., Larcher F., Del Rio M.Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res., 2004, 64, 5632-5642.
85. Subramanian P., Notario P.M., Becerra S.P. Pigment epitheliumderived factor receptor (PEDF-R): a plasma membrane-linked phospholipase with PEDF binding affinity. Adv. Exp. Med. Biol., 2010, 664, 29-37.
86. Guan M., Jiang H., Xu C., Xu R., Chen Z., Lu Y. Adenovirusmediated PEDF expression inhibits prostate cancer cell growth and results in augmented expression of PAI-2. Cancer Biol. Ther., 2007, 6, 419-425.
87. Wu Q.J., Gong C.Y., Luo S.T., Zhang D.M., Zhang S., Shi H.S., Lu L., Yan H.X., He S.S., Li D.D., Yang L., Zhao X., Wei Y.Q. AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis model. BMC Cancer, 2012, 12, 129-137.
88. He S.S., Shi H.S., Yin T., Li Y.X., Luo S.T., Wu Q.J., Lu L., Wei Y.Q., Yang L. AAV-mediated gene transfer of human pigment epithelium-derived factor inhibits Lewis lung carcinoma growth in mice. Oncol. Rep., 2012, 4, 1142-1148.
89. Gao Y., Yao A., Zhang W., Lu S., Yu Y., Deng L., Yin A., Xia Y., Sun B., Wang X. Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice. Oncogene, 2010, 29, 2784-2794.
90. Yang L.P., Cheng P., Peng X.C., Shi H.S., He W.H., Cui F.Y., Luo S.T., Wei Y.Q., Yang L. Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma. J. Exp. Clin. Cancer Res., 2009, 28, 75-85.
91. Miranda E., Lomas D.A. Neuroserpin: a serpin to think about. Cell Mol. Life Sci., 2006, 63, 709-722.
92. Yepes M., Sandkvist M., Wong M.K.K., Coleman T.A., Smith E., Cohan S.L., Lawrence D.A. Neuroserpin reduces cerebral infarct volume and protects neurones from ischaemia-induced apoptosis. Blood, 2000, 96, 569-576.
93. Cinelli P., Madani R., Tsuzuki N., Vallet P., Arras M., Zhao C.N., Osterwalder T., Rülicke T., Sonderegger P. Neuroserpin, a neuroprotective factor in focal ischaemic stroke. Mol. Cell. Neurosci., 2001, 18, 443-457.
94. Yepes M., Sandkvist M., Coleman T. A., Moore E., Wu J.-Y., Mitola D., Bugge T.H., Lawrence DA. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen independent. J. Clin. Invest., 2002, 109, 1571-1578.
95. Davis R. L., Shrimpton A. E., Holohan P. D., Bradshaw C., Feiglin D., Sonderegger P., Kinter J., Becker L.M., Lacbawan F., Krasnewich D., Muenke M., Lawrence D.A., Yerby M.S., Shaw C.M., Gooptu B., Elliott P.R., Finch J.T., Carrell R.W., Lomas D.A. Familial dementia caused by polymerisation of mutant neuroserpin. Nature, 1999, 401, 376-379.
96. Hasumi H., Ishiguro H., Nakamura M., Sugiura S., Osada Y., Miyoshi Y., Fujinami K., Yao M., Hamada K., Yamada-Okabe H., Kubota Y., Uemura H. Neuroserpin (PI-12) is upregulated in highgrade prostate cancer and is associated with survival. Int. J. Cancer., 2005, 115, 911-916.
97. Yamanaka S., Olaru A.V., An F., Luvsanjav D., Jin Z., Agarwal R., Tomuleasa C., Popescu I., Alexandrescu S., Dima S., Chivu-Economescu M., Montgomery E.A., Torbenson M., Meltzer S.J., Selaru F.M. MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer. Dig. Liver Dis., 2012, 44, 589-596.
98. Upton C., Macen J.L., Wishart D.S., McFadden G. Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence. Virology, 1990, 179, 618-631.
99. Macen J.L., Upton C., Nation N., McFadden G l. SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology, 1993, 195, 348-363.
100. Viswanathan K., Richardson J., Togonu-Bickersteth B., Dai E., Liu L., Vatsya P., Sun Y.M., Yu J., Munuswamy-Ramanujam G., Baker H., Lucas A.R. Myxoma viral serpin, Serp-1, inhibits human monocyte adhesion through regulation of actin-binding protein filamin B. J. Leukoc. Biol., 2009, 85, 418-426.
101. Dai E., Guan H., Liu L., Little S., McFadden G., Vaziri S., Cao H., Ivanova I.A., Bocksch L., Lucas A. Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J. Biol. Chem., 2003, 278, 18563-18572.
102. Lucas, A., Dai, E., Liu, L., Guan, H., Nash, P., McFadden, G., et al. Transplant vasculopathy: viral anti-inflammatory serpin regulation of atherogenesis. J. Heart Lung Transplant., 2000, 19, 1029-1038.
103. Miller L.W., Dai E., Nash P., Liu L., Icton C., Klironomos D., Fan L., Nation P.N., Zhong R., McFadden G., Lucas A. Inhibition of transplant vasculopathy in a rat aortic allograft model after infusion of anti-inflammatory viral serpin. Circulation, 2000, 101, 1598-1605.
104. Zheng D., Chen H., Bartee MY., Williams J., Davids JA., Huang E., Moreb J., Lucas A. Virus-derived anti-inflammatory proteins: potential therapeutics for cancer. Trends Mol. Med., 2012, 18, 304-310.
105. Richardson M., Liu L., Dunphy L., Wong D., Sun Y., Viswanathan K., Singh G., Lucas A. Viral serpin, Serp-1, inhibits endogenous angiogenesis in the chicken chorioallantoic membrane model. Cardiovasc. Pathol., 2007, 16, 191-202.